Healthcare
ByCan Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Are China’s Innovation and Cost Advantages Redrawing Global Biopharma Competition?
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
